The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Statins and cancer prevention
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Sudbø, J., Lee, J., Lippman, S., Mork, J., Sagen, S., Flatner, N., Ristimaki, A. P., Sudbø, A., Mao, L., Zhou, X. K., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67488-0 · Cited by 78
Self-citationRetractedPrevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
Self-citationPLEIOTROPIC EFFECTS OF STATINS
Liao, J. K., & Laufs, U. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095748 · Cited by 1,994
Kureishi, Y., Luo, Z., Shiojima, I., Bialik, A., Fulton, D., Lefer, D. J., Sessa, W. C., & Walsh, K. (2000) · Nature Medicine · doi:10.1038/79510 · Cited by 1,439
Ridker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F. M., Moye, L. A., Goldman, S., Flaker, G. C., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.98.9.839 · Cited by 1,389
Youssef, S., Stüve, O., Patarroyo, J. C., Ruiz, P. J., Radosevich, J. L., Hur, E. M., Bravo, M., Mitchell, D. J., Sobel, R. A., Steinman, L., et al. (2002) · Nature · doi:10.1038/nature01158 · Cited by 1,097
Aspirin and the Risk of Colorectal Cancer in Women
Giovannucci, E., Egan, K. M., Hunter, D. J., Stampfer, M. J., Colditz, G. A., Willett, W. C., & Speizer, F. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509073331001 · Cited by 1,090
Weitz-Schmidt, G., Welzenbach, K., Brinkmann, V., Kamata, T., Kallen, J., Bruns, C., Cottens, S., Takada, Y., & Hommel, U. (2001) · Nature Medicine · doi:10.1038/89058 · Cited by 1,041
Statins and the Risk of Colorectal Cancer
Poynter, J. N., Gruber, S. B., Higgins, P. D. R., Almog, R., Bonner, J. D., Rennert, H. S., Low, M., Greenson, J. K., & Rennert, G. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043792 · Cited by 816
Self-citationHebert, P. R. (1997) · JAMA · doi:10.1001/jama.1997.03550040069040 · Cited by 740
Statins Have Biphasic Effects on Angiogenesis
Weis, M., Heeschen, C., Glassford, A. J., & Cooke, J. P. (2002) · Circulation · doi:10.1161/hc0602.103393 · Cited by 680
The statins as anticancer agents.
Chan, K., Oza, A. M., & Siu, L. L. (2003) · PubMed · Cited by 618
Wong, W. W.-L., Dimitroulakos, J., Minden, M., & Penn, L. (2002) · Leukemia · doi:10.1038/sj.leu.2402476 · Cited by 578
Gotto, A. M., Whitney, E., Stein, E. A., Shapiro, D. R., Clearfield, M., Weis, S., Jou, J. Y., Langendörfer, A., Beere, P. A., Watson, D. J., et al. (2000) · Circulation · doi:10.1161/01.cir.101.5.477 · Cited by 563
Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development
Rowinsky, E. K., Windle, J. J., & Von Hoff, D. D. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3631 · Cited by 537
C-Reactive Protein and the Risk of Incident Colorectal Cancer
Erlinger, T. P. (2004) · JAMA · doi:10.1001/jama.291.5.585 · Cited by 533
The Risk of Cancer in Users of Statins
Graaf, M. R., Beiderbeck, A. B., Egberts, A. C. G., Richel, D. J., & Guchelaar, H.-J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.027 · Cited by 528
HEBERT, P. R., GAZIANO, J. M., CHAN, K. S., & HENNEKENS, C. H. (1998) · Survey of Anesthesiology · doi:10.1097/00132586-199806000-00060 · Cited by 506
Sterols and Isoprenoids: Signaling Molecules Derived from the Cholesterol Biosynthetic Pathway
Edwards, P. A., & Ericsson, J. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.157 · Cited by 458
Fritz, G., Brachetti, C., Bahlmann, F., Schmidt, M., & Kaina, B. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600510 · Cited by 381
Carcinogenicity of Lipid-Lowering Drugs
Newman, T. B. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530250059028 · Cited by 380
Statins as anti-inflammatory agents
Weitz-Schmidt, G. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02077-1 · Cited by 354
Rao, S., Porter, D. C., Chen, X., Herliczek, T., Lowe, M., & Keyomarsi, K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.14.7797 · Cited by 345
Mo, H., & Elson, C. E. (2004) · Experimental Biology and Medicine · doi:10.1177/153537020422900701 · Cited by 340
Strandberg, T. E., Pyörälä, K., Cook, T. J., Wilhelmsen, L., Faergeman, O., Thorgeirsson, G., Pedersen, T. R., & Kjekshus, J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16936-5 · Cited by 331
Blais, L., Desgagné, A., & LeLorier, J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.15.2363 · Cited by 326
Double-Edged Role of Statins in Angiogenesis Signaling
Urbich, C., Dernbach, E., Zeiher, A. M., & Dimmeler, S. (2002) · Circulation Research · doi:10.1161/01.res.0000014081.30867.f8 · Cited by 305
Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer
Graaf, M. R., Richel, D. J., van Noorden, C. J. F., & Guchelaar, H.-J. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.06.010 · Cited by 300
Wang, C., Gale, M., Keller, B. C., Huang, H., Brown, M. S., Goldstein, J. L., & Ye, J. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.004 · Cited by 299
Cell cycle-specific effects of lovastatin.
Jakóbisiak, M., Bruno, S., Skierski, J. S., & Darzynkiewicz, Z. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.9.3628 · Cited by 295
Isoprenoids Suppress the Growth of Murine B16 Melanomas In Vitro and In Vivo
He, L., Mo, H., Hadisusilo, S., Qureshi, A. A., & Elson, C. E. (1997) · The Journal of Nutrition · doi:10.1093/jn/127.5.668 · Cited by 290
Cancer risk among statin users: A population‐based cohort study
Friis, S., Poulsen, A. H., Johnsen, S. P., McLaughlin, J. K., Fryzek, J. P., Dalton, S. O., Sørensen, H. T., & Olsen, J. H. (2005) · International Journal of Cancer · doi:10.1002/ijc.20758 · Cited by 275
Shepherd, J., Blauw, G. J., & Murphy, M. B. (2003) · ACC Current Journal Review · doi:10.1016/s1062-1458(03)00040-0 · Cited by 273
Pillé, J.-Y., Denoyelle, C., Varet, J., Bertrand, J.-R., Soria, J., Opolon, P., Lu, H., Pritchard, L.-L., Vannier, J.-P., Malvy, C., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.08.029 · Cited by 263
Statins Exert Endothelial Atheroprotective Effects via the KLF2 Transcription Factor
Parmar, K. M., Nambudiri, V., Dai, G., Larman, H. B., Gimbrone, M. A., & García-Cardeña, G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500144200 · Cited by 253
Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells
Cafforio, P., Dammacco, F., Gernone, A., & Silvestris, F. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi036 · Cited by 250
Statin use and cancer risk in the General Practice Research Database
Kaye, J. A., & Jick, H. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601566 · Cited by 248
Pfeffer, M. A., Keech, A., Sacks, F. M., Cobbe, S. M., Tonkin, A., Byington, R. P., Davis, B. R., Friedman, C. P., & Braunwald, E. (2002) · Circulation · doi:10.1161/01.cir.0000017634.00171.24 · Cited by 241
Bourguignon, L. Y. W., Singleton, P. A., Zhu, H., & Diedrich, F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301885200 · Cited by 237
Attoub, S., Noe, V., Pirola, L., Bruyneel, E., Chastre, E., Mareel, M., Wymann, M. P., & Gespach, C. (2000) · The FASEB Journal · doi:10.1096/fj.00-0162 · Cited by 235
Statins and Prostate Cancer Risk: A Case-Control Study
Shannon, J., Tewoderos, S., Garzotto, M., Beer, T. M., Derenick, R., Palma, A., & Farris, P. E. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi203 · Cited by 232
Wu, J., Wong, W. W.-L., Khosravi, F., Minden, M. D., & Penn, L. Z. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0866 · Cited by 225
Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP.
Marcelli, M., Cunningham, G. R., Haidacher, S. J., Padayatty, S. J., Sturgis, L., Kagan, C., & Denner, L. A. (1998) · PubMed · Cited by 210
Intensive Statin Therapy — A Sea Change in Cardiovascular Prevention
Topol, E. J. (2004) · New England Journal of Medicine · doi:10.1056/nejme048061 · Cited by 197
Do statins cause cancer? A meta-analysis of large randomized clinical trials
Bjerre, L. M., & LeLorier, J. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00705-7 · Cited by 195
Potential antitumor effects of statins (Review)
Jakobisiak, M., & Golab, J. (2003) · International Journal of Oncology · doi:10.3892/ijo.23.4.1055 · Cited by 193
Kusama, T., Mukai, M., Iwasaki, T., Tatsuta, M., Matsumoto, Y., Akedo, H., & Nakamura, H. (2001) · PubMed · Cited by 187
Agarwal, B., Rao, C. V., Bhendwal, S., Ramey, W. R., Shirin, H., Reddy, B. S., & Holt, P. R. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70342-2 · Cited by 185
Winter-Vann, A. M., Baron, R. A., Wong, W., dela Cruz, J., York, J. D., Gooden, D. M., Bergo, M. O., Young, S. G., Toone, E. J., & Casey, P. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408107102 · Cited by 178 · cited 1×
“2 ) as novel targets in neoplasia (for example, colorectal cancer and melanoma”
BackgroundSingh, A., Karnoub, A. E., Palmby, T. R., Lengyel, E., Sondek, J., & Der, C. J. (2004) · Oncogene · doi:10.1038/sj.onc.1208182 · Cited by 174
Role of Rho-family proteins in cell adhesion and cancer
Malliri, A., & Collard, J. G. (2003) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(03)00098-x · Cited by 172
Hakamada-Taguchi, R., Uehara, Y., Kuribayashi, K., Numabe, A., Saito, K., Negoro, H., Fujita, T., Toyo-oka, T., & Kato, T. (2003) · Circulation Research · doi:10.1161/01.res.0000101298.76864.14 · Cited by 172
Gerber, J. G., Rosenkranz, S. L., Fichtenbaum, C. J., Vega, J. M., Yang, A., Alston, B. L., Brobst, S. W., Segal, Y., & Aberg, J. A. (2005) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000167156.44980.33 · Cited by 167
Might treatment of hypercholesterolaemia increase non-cardiac mortality?
Oliver, M. F. (1991) · The Lancet · doi:10.1016/0140-6736(91)93208-q · Cited by 160
Lipid-Lowering Drug Use and Breast Cancer in Older Women: A Prospective Study
Cauley, J. A., Zmuda, J. M., Lui, L., Hillier, T. A., Ness, R. B., Stone, K. L., Cummings, S. R., & Bauer, D. C. (2003) · Journal of Women s Health · doi:10.1089/154099903322447710 · Cited by 154
Functional Analysis of the Contribution of RhoA and RhoC GTPases to Invasive Breast Carcinoma
Simpson, K. J., Dugan, A. S., & Mercurio, A. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2247 · Cited by 154
Zhang, Y., Holford, T. R., Leaderer, B. P., Zahm, S. H., Boyle, P., Morton, L. M., Zhang, B., Zou, K., Flynn, S. D., Tallini, G., et al. (2004) · Cancer Causes & Control · doi:10.1023/b:caco.0000027506.55846.5d · Cited by 152
Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells.
Collisson, E. A., Kleer, C. G., Wu, M., De, A., Gambhir, S. S., Merajver, S. D., & Kolodney, M. S. (2003) · PubMed · Cited by 151
Mueck, A. O., Seeger, H., & Wallwiener, D. R. (2003) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000055485.06076.00 · Cited by 151
Alonso, D. F., Fariña, H. G., Skilton, G., Gabri, M. R., Lorenzo, M. S. D., & Gomez, D. E. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006058409974 · Cited by 146
Statins for Atherosclerosis — As Good as It Gets?
Ehrenstein, M. R., Jury, E. C., & Mauri, C. (2005) · New England Journal of Medicine · doi:10.1056/nejme048326 · Cited by 138
Statin Use and the Risk of Breast and Prostate Cancer
Coogan, P. F., Rosenberg, L. A., Palmer, J. R., Strom, B. L., Zauber, A. G., & Shapiro, S. (2002) · Epidemiology · doi:10.1097/00001648-200205000-00005 · Cited by 137
Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis
Gniadecki, R. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.05.145 · Cited by 134
Statins differ in their ability to block NF-kB activation in human blood monocytes
Hilgendorff, A., Muth, H., Parviz, B., Staubitz, A., Haberbosch, W., Tillmanns, H., & Hölschermann, H. (2003) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp41397 · Cited by 130
Vincent, L., Soria, C., Mirshahi, F., Opolon, P., Mishal, Z., Vannier, J., Soria, J., & Li, H. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000012283.15789.67 · Cited by 129
Denoyelle, C., Albanese, P., Uzan, G., Li, H., Vannier, J., Soria, J., & Soria, C. (2003) · Cellular Signalling · doi:10.1016/s0898-6568(02)00124-9 · Cited by 120
Shibata, M., Ito, Y., Morimoto, J., & Otsuki, Y. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh201 · Cited by 119
Boudreau, D. M., Gardner, J. S., Malone, K. E., Heckbert, S. R., Blough, D. K., & Daling, J. R. (2004) · Cancer · doi:10.1002/cncr.20271 · Cited by 116
Lovastatin-induced apoptosis in human melanoma cell lines
Shellman, Y. G., Ribble, D., Miller, L. A., Gendall, J., VanBuskirk, K., Kelly, D., Norris, D. A., & Dellavalle, R. P. (2005) · Melanoma Research · doi:10.1097/00008390-200504000-00001 · Cited by 116
Cancer prevention science and practice.
Lippman, S. M., & Hong, W. K. (2002) · PubMed · Cited by 112
Self-citationVeillard, N. R., & Mach, F. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/pl00012505 · Cited by 107
Targeting the Mevalonate Pathway Inhibits the Function of the Epidermal Growth Factor Receptor
Mantha, A. J., Hanson, J. E. L., Goss, G., Lagarde, A. E., Lorimer, I. A., & Dimitroulakos, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1951 · Cited by 101
Inhibition of Rho Is Required for cAMP-induced Melanoma Cell Differentiation
Buscà, R., Bertolotto, C., Abbe, P., Englaro, W., Ishizaki, T., Narumiya, S., Boquet, P., Ortonne, J. P., & Ballotti, R. (1998) · Molecular Biology of the Cell · doi:10.1091/mbc.9.6.1367 · Cited by 100
Chemopreventive effect of farnesol and lanosterol on colon carcinogenesis
Rao, C. V., Newmark, H. L., & Reddy, B. S. (2002) · Cancer Detection and Prevention · doi:10.1016/s0361-090x(02)00119-8 · Cited by 97
Statin use and the risk of breast cancer
Beck, P., Wysowski, D. K., Downey, W., & Butler-Jones, D. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(02)00614-5 · Cited by 97
Statins Can Inhibit Proliferation of Human Breast Cancer Cells in Vitro
Seeger, H., Wallwiener, D. R., & Mueck, A. O. (2003) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2003-37501 · Cited by 96
Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation
Houten, S. M., Frenkel, J., & Waterham, H. R. (2003) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-2296-4 · Cited by 96
Statin therapy and angiogenesis
Skaletz‐Rorowski, A., & Walsh, K. X. (2003) · Current Opinion in Lipidology · doi:10.1097/00041433-200312000-00008 · Cited by 93
Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models
Shibata, M. (2003) · Carcinogenesis · doi:10.1093/carcin/24.3.453 · Cited by 92
Statins and Cancer Development
Duncan, R. E., El‐Sohemy, A., & Archer, M. C. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0027 · Cited by 90
Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells
Agarwal, B., Halmos, B., Feoktistov, A. S., Protiva, P., Ramey, W. G., Chen, M., Pothoulakis, C., LaMont, J. T., & Holt, P. R. (2002) · Carcinogenesis · doi:10.1093/carcin/23.3.521 · Cited by 89
Maltese, W. A., & Sheridan, K. M. (1985) · Journal of Cellular Physiology · doi:10.1002/jcp.1041250326 · Cited by 87
Statin use, hyperlipidaemia, and the risk of breast cancer
Kaye, J. A., Meier, C. R., Walker, A. M., & Jick, H. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600267 · Cited by 87
Katano, H., Pesnicak, L., & Cohen, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0305149101 · Cited by 87
Skaletz‐Rorowski, A., Lutchman, M., Kureishi, Y., Lefer, D., Faust, J. R., & Walsh, K. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00618-1 · Cited by 85
Ukomadu, C., & Dutta, A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307194200 · Cited by 84
Sata, M., Nishimatsu, H., Osuga, J.-I., Tanaka, K., Ishizaka, N., Ishibashi, S., Hirata, Y., & Nagai, R. (2004) · Hypertension · doi:10.1161/01.hyp.0000126186.29571.41 · Cited by 83
Lovastatin-induced Apoptosis of Human Medulloblastoma Cell Lines in vitro
Macaulay, R. J. B., Wang, W., Dimitroulakos, J., Becker, L. E., & Yeger, H. (1999) · Journal of Neuro-Oncology · doi:10.1023/a:1006164406202 · Cited by 78
Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death
Park, C. (2001) · Carcinogenesis · doi:10.1093/carcin/22.10.1727 · Cited by 77
The Rho-ADP-ribosylating C3 exoenzyme from Clostridium botulinum and related C3-like transferases
Wilde, C., & Aktories, K. (2001) · Toxicon · doi:10.1016/s0041-0101(01)00152-0 · Cited by 74
Sterol‐independent regulation of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase in tumor cells
Hentosh, P., Yuh, S. H., Elson, C. E., & Peffley, D. M. (2001) · Molecular Carcinogenesis · doi:10.1002/mc.1074 · Cited by 73
Geranylgeraniol Overcomes the Block of Cell Proliferation by Lovastatin in C6 Glioma Cells
Crick, D. C., Andres, D., Danesi, R., Macchia, M., & Waechter, C. J. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70062397.x · Cited by 70
Fariña, H. G., Bublik, D. R., Alonso, D. F., & Gomez, D. E. (2002) · Clinical & Experimental Metastasis · doi:10.1023/a:1020355621043 · Cited by 67
Improved Lymphocyte Function-associated Antigen-1 (LFA-1) Inhibition by Statin Derivatives
Weitz‐Schmidt, G., Welzenbach, K., Dawson, J., & Kallen, J. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407951200 · Cited by 67
Narisawa, T., Morotomi, M., Fukaura, Y., Hasebe, M., Ito, M., & Aizawa, R. (1996) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1996.tb02103.x · Cited by 66
Pro-apoptotic effect of fluvastatin on human smooth muscle cells
Buemi, M., Allegra, A., Senatore, M., Marino, D., Medici, M. A., Aloisi, C., Pasquale, G. D., & Corica, F. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00122-3 · Cited by 63
Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells
Mazières, J., Tillement, V., Allal, B., Clanet, C., Bobin, L., Chen, Z., Sebti, S. M., Favre, G., & Pradines, A. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.10.019 · Cited by 63
Caraglia, M., Budillon, A., Tagliaferri, P., et al. (2005) · Current Drug Targets · doi:10.2174/1389450053765833 · Cited by 53
Effects of perillyl alcohol on melanoma in the TPras mouse model.
Lluria-Prevatt, M., Morreale, J., Gregus, J., Alberts, D. S., Kaper, F., Giaccia, A. J., & Powell, M. B. (2002) · PubMed · Cited by 49
Inverted signaling hierarchy between RAS and RAC in T-lymphocytes
Zugaza, J. L., Caloca, M. J., & Bustelo, X. R. (2004) · Oncogene · doi:10.1038/sj.onc.1207768 · Cited by 42
Melanoma Chemoprevention: A Role for Statins or Fibrates?
Dellavalle, R. P., Nicholas, M. K., & Schilling, L. M. (2003) · American Journal of Therapeutics · doi:10.1097/00045391-200305000-00007 · Cited by 38
Lovastatin and simvastatin are modulators of the proteasome
Wójcik, C., Bury, M., Stokłosa, T., Giermasz, A., Feleszko, W., Młynarczuk-Biały, I., Pleban, E., Basak, G. W., Ōmura, S., & Jakóbisiak, M. (2000) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(00)00044-3 · Cited by 38
The Isoprenoid Substrate Specificity of Isoprenylcysteine Carboxylmethyltransferase
Anderson, J. L., Henriksen, B. S., Gibbs, R. A., & Hrycyna, C. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504982200 · Cited by 38
Tilkin‐Mariamé, A., Cormary, C., Ferro, N., Sarrabayrouse, G., Lajoie‐Mazenc, I., Faye, J., & Favre, G. (2005) · The FASEB Journal · doi:10.1096/fj.04-3482fje · Cited by 36
Collisson, E. A., Carranza, D. C., Chen, I. Y., & Kolodney, M. S. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2002.19519.x · Cited by 34
Osteoblast-derived Oxysterol Is a Migration-inducing Factor for Human Breast Cancer Cells
Silva, J., Beckedorf, A. I., & Bieberich, E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301233200 · Cited by 33
Statins and cancer: a case of meta-uncertainty
Güallar, E., & Goodman, S. N. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00758-6 · Cited by 14
Breast cancer inhibition by statins
Esserman, L. J., Campbell, M. J., Shoemaker, M., Lobo, M., Marx, C., & Benz, C. C. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.1003 · Cited by 13
Cited by
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855
Acetyl coenzyme A: a central metabolite and second messenger
Pietrocola, F., Galluzzi, L., Bravo-San Pedro, J. M., Madeo, F., & Kroemer, G. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.014 · Cited by 1,378
Statin use and reduced cancer-related mortality
Nielsen, S. F., Nordestgaard, B. G., & Bojesen, S. E. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201735 · Cited by 1,030
Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
Albini, A., Pennesi, G., Donatelli, F., Cammarota, R., De Flora, S., & Noonan, D. M. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp440 · Cited by 839
The tumour microenvironment as a target for chemoprevention
Albini, A., & Sporn, M. B. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2067 · Cited by 823
Metadata
- Authors
- Demierre, M.-F., Higgins, P. D. R., Gruber, S. B., Hawk, E., & Lippman, S. M.
- Venue
- Nature Reviews Cancer
- Published
- 2005-12
- Volume
- 5
- Issue
- 12
- Pages
- 930-942
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2155421604
- Cited by
- 819
- References
- 117
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.